<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="{font-family : courier ; font-style : italic;} Emerg Infect DisEIDEmerging" exact="Infectious" post="Diseases1080-60401080-6059Centers for Disease Control and Prevention pmcid: 3291404 pmid:"/>
 <result pre="; font-style : italic;} Emerg Infect DisEIDEmerging Infectious Diseases1080-60401080-6059Centers for" exact="Disease" post="Control and Prevention pmcid: 3291404 pmid: 1649471805-1068 doi: 10.3201/eid1201.051068"/>
 <result pre="only vaccines and antiviral drugs are clearly efficacious in preventing" exact="infection" post="or treating illness. Unless the pandemic strain closely resembles"/>
 <result pre="value in prevention. Thus, few studies have been undertaken. Similarly," exact="symptomatic" post="therapy is possible and perhaps appropriate in treating milder"/>
 <result pre="appropriate in treating milder illnesses. Antimicrobial drugs are necessary when" exact="bacterial" post="complications occur. However, antiviral drugs are specific and can"/>
 <result pre="However, antiviral drugs are specific and can not only prevent" exact="infection" post="but also treat illness (1). A pandemic virus will"/>
 <result pre="a virus variant thought to have pandemic potential (2). The" exact="swine influenza" post="virus, detected in humans in that year, was viewed"/>
 <result pre="threat. Because the pandemic never occurred, researchers had time to" exact="complete" post="a large range of pediatric and adult studies. We"/>
 <result pre="had time to complete a large range of pediatric and" exact="adult" post="studies. We learned that those who had no previous"/>
 <result pre="used could not be given to those persons without frequent" exact="systemic" post="reactions, but the whole-virus vaccine was more immunogenic and"/>
 <result pre="current observations. At one time, a closed, fixed cycle of" exact="type A" post="subtypes was thought to exist, with one following the"/>
 <result pre="epidemiologic characteristics. As shown in the Table, the concern that" exact="swine influenza" post="would appear in 1976 was supported by seroarcheology, evidence"/>
 <result pre="Asian H2N2 1968 Hong Kong H3N2 1976 Swine H1N1† 1977" exact="Russian" post="H1N1 *Unknown N subtype. †Limited human-to-human transmission. The question, then,"/>
 <result pre="to prepare a vaccine to control the next pandemic? Will" exact="type A" post="(H2N2) return, in keeping with the recycling theory? Much"/>
 <result pre="with little or no further transmission, but has not produced" exact="disease" post="with high case fatality (11). The highly pathogenic type"/>
 <result pre="produced disease with high case fatality (11). The highly pathogenic" exact="type A" post="(H5N1) virus is at the top of the list"/>
 <result pre="the list since fewer transmissions to humans and less clinical" exact="disease" post="have been seen (14,15). Prepandemic Vaccine Evaluation Scientific questions"/>
 <result pre="of immune response, population likely to be infected, and expected" exact="disease" post="characteristics. Also, that virus presents the fewest issues about"/>
 <result pre="whole-virus vaccines evaluated in 1976 (16). In persons without prior" exact="infection" post="with this virus, 1 injection of as little as"/>
 <result pre="those produced in 1976. Less work has been done with" exact="avian influenza," post="A (H9N2), but similar approaches might be used with"/>
 <result pre="using reverse genetics, but on a background of the high-growth" exact="type A" post="virus, PR8 (18). Producing vaccine by using this engineered"/>
 <result pre="response to some avian viruses is also an issue. Even" exact="infection" post="with the A (H5N1) virus does not produce a"/>
 <result pre="to be effective against a pandemic virus. Adamantane action is" exact="limited" post="to type A viruses, but all pandemic viruses are"/>
 <result pre="effective against a pandemic virus. Adamantane action is limited to" exact="type A" post="viruses, but all pandemic viruses are type A (15)."/>
 <result pre="limited to type A viruses, but all pandemic viruses are" exact="type A" post="(15). The neuraminidases of many different type A viruses"/>
 <result pre="viruses are type A (15). The neuraminidases of many different" exact="type A" post="viruses have been evaluated with respect to NAIs, and"/>
 <result pre="may be more efficacious in preventing febrile illnesses, although asymptomatic" exact="infection" post="often still occurs. This characteristic is actually desirable, since"/>
 <result pre="next wave of the pandemic virus. However, in some cases," exact="infection" post="is prevented completely, so vaccine should be used when"/>
 <result pre="sufficient to conclude that they produced more rapid resolution than" exact="symptomatic" post="therapy, such as aspirin (25). No data suggest that"/>
 <result pre="with the adamantanes, and the mutant viruses may be less" exact="infectious" post="and transmissible than wild type (28–30). This conclusion cannot"/>
 <result pre="resistance has apparently occurred with adamantanes, and the more recent" exact="type A" post="(H5N1) virus, as well as some currently circulating seasonal"/>
 <result pre="symptomatic. With ordinary influenza viruses of pandemic potential, such as" exact="type A" post="(H2N2) and A (H9N2), treatment success in the interpandemic"/>
 <result pre="the pandemic. Such may not be the case with the" exact="type A" post="(H5N1) virus. The virus has evolved since the 1997"/>
 <result pre="the 1997 Hong Kong outbreak, and some evidence of a" exact="systemic" post="infection involving the brain and gastrointestinal tract exists (12,34)."/>
 <result pre="1997 Hong Kong outbreak, and some evidence of a systemic" exact="infection" post="involving the brain and gastrointestinal tract exists (12,34). This"/>
 <result pre="infection involving the brain and gastrointestinal tract exists (12,34). This" exact="infection" post="has also been demonstrated in laboratory animals such as"/>
 <result pre="to reach adequate concentration in these sites, remote from the" exact="respiratory" post="tract. Zanamivir is not orally bioavailable and is thus"/>
 <result pre="such studies have been difficult to carry out, since the" exact="disease" post="has been occurring in areas where recognition of the"/>
 <result pre="results that have been described with this drug in the" exact="limited" post="case reports are due to late treatment or other"/>
 <result pre="guide treatment of human cases until more data are available." exact="Mouse" post="studies have already indicated that, while oseltamivir is effective,"/>
 <result pre="would not be useful. This assumption means that if the" exact="disease" post="is systemic and case fatality is high, among the"/>
 <result pre="be useful. This assumption means that if the disease is" exact="systemic" post="and case fatality is high, among the NAIs only"/>
 <result pre="would be useful, since it is absorbed (39). Given the" exact="limited" post="quantities likely to be available, at least in the"/>
 <result pre="appropriate. Seasonal prophylaxis uses larger quantities of drug, but possibly" exact="limited" post="postexposure use could be feasible. Zanamivir, if available, might"/>
 <result pre="feasible. Zanamivir, if available, might find its role in prevention." exact="Infection" post="is likely through the respiratory tract, and given past"/>
 <result pre="find its role in prevention. Infection is likely through the" exact="respiratory" post="tract, and given past evidence, the drug could make"/>
 <result pre="for clinical evaluation, and drugs targeting other phases of influenza" exact="viral" post="replication would be especially useful. Given the threat of"/>
 <result pre="that the approach might be more likely to succeed with" exact="partial" post="immunity in the population (42). This immunity could be"/>
 <result pre="models will be necessary, given the sporadic nature of the" exact="disease" post="in humans. Overall, developing countries will have limited access"/>
 <result pre="of the disease in humans. Overall, developing countries will have" exact="limited" post="access to vaccines and antiviral drugs, and their needs"/>
 <result pre="of RWY-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other" exact="avian influenza" post="viruses.Antimicrob Agents Chemother. 2001;45:2723–3210.1128/AAC.45.10.2723-2732.200111557461 2. WrightPF, ThompsonJ, VaughnWK, FollandDS,"/>
 <result pre="MunsterV, et al.Avian influenza A virus (H7N7) associated with human" exact="conjunctivitis" post="and a fatal case of acute respiratory distress syndrome.Proc"/>
 <result pre="(H7N7) associated with human conjunctivitis and a fatal case of" exact="acute" post="respiratory distress syndrome.Proc Natl Acad Sci U S A."/>
 <result pre="associated with human conjunctivitis and a fatal case of acute" exact="respiratory" post="distress syndrome.Proc Natl Acad Sci U S A. 2004;101:1356–6110.1073/pnas.030835210014745020"/>
 <result pre="2004;101:1356–6110.1073/pnas.030835210014745020 15. HirstM, AstellCR, GriffithM, CoughlinSM, MoksaM, ZengT, et al.Novel" exact="avian influenza" post="H7N3 strain outbreak, British Columbia.Emerg Infect Dis. 2004;10:2192–515663859 16."/>
 <result pre="RoweT, Hu-PrimmerJ, LuX, et al.Antibody response in individuals infected with" exact="avian influenza" post="A (H5N1) viruses and detection of anti-H5 antibody among"/>
 <result pre="contacts.J Infect Dis. 1999;180:1763–7010.1086/31513710558929 22. MontoAS, GunnRA, BandykMG, KingCLPrevention of" exact="Russian" post="influenza by amantadine.JAMA. 1979;241:1003–710.1001/jama.1979.03290360019018368354 23. MontoAS, RobinsonDP, HerlocherML, HinsonJMJr,"/>
 <result pre="fever and symptoms in young adults with influenza A/Brazil/78 H1N1" exact="infection" post="after treatment with aspirin or amantadine.Antimicrob Agents Chemother. 1983;23:577–826859836"/>
 <result pre="KeeneON, HammondJMJ, ElliottM, HaydenFGImpact of zanamivir on antibiotic use for" exact="respiratory" post="events following acute influenza in adolescents and adults.Arch Intern"/>
 <result pre="HaydenFGImpact of zanamivir on antibiotic use for respiratory events following" exact="acute" post="influenza in adolescents and adults.Arch Intern Med. 2000;160:3234–4010.1001/archinte.160.21.323411088083 32."/>
 <result pre="WatC, MillsT, MahoneyP, WardP, HaydenFGImpact of oseltamivir treatment on influenza-related" exact="lower" post="respiratory tract complications and hospitalizations.Arch Intern Med. 2003;163:1667–7210.1001/archinte.163.14.166712885681 33."/>
 <result pre="MillsT, MahoneyP, WardP, HaydenFGImpact of oseltamivir treatment on influenza-related lower" exact="respiratory" post="tract complications and hospitalizations.Arch Intern Med. 2003;163:1667–7210.1001/archinte.163.14.166712885681 33. MontoAS,"/>
 <result pre="34. de JongMD, BachVC, PhanTQ, VoMH, TranTT, NguyenBH, et al.Fatal" exact="avian influenza" post="A (H5N1) in a child presenting with diarrhea followed"/>
 <result pre="al.Fatal avian influenza A (H5N1) in a child presenting with" exact="diarrhea" post="followed by coma.N Engl J Med. 2005;352:686–9110.1056/NEJMoa04430715716562 35. GovorkovaEA,"/>
 <result pre="BugariniR, NicholsonKG, PoddaA, WoodJM, ZambonMC, et al.Cross-reactivity to highly pathogenic" exact="avian influenza" post="H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza"/>
 <result pre="4071.Antimicrob Agents Chemother. 1998;42:647–539517946 40. MontoASPerspective: the threat of an" exact="avian influenza" post="pandemic.N Engl J Med. 2005;352:323–510.1056/NEJMp04834315668220 41. FergusonNM, CummingsD, CauchemezS,"/>
</results>
